Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Glecaprevir/Pibrentasvir in HCV-HIV Coinfection
Clin Infect Dis; ePub 2018 Mar 16; Rockstroh, et al
Glecaprevir/pibrentasvir for 8 weeks in non-cirrhotic and 12 weeks in cirrhotic patients is a highly efficacious and well-tolerated treatment for hepatitis C virus/human immunodeficiency virus-1 (HCV/HIV), a recent study found. This is regardless of baseline HCV viral load or prior treatment with interferon or sofosbuvir, according to results from EXPEDITION-2, a phase 3, multicenter, open-label study evaluating glecaprevir/pibrentasvir (300 mg/120 mg) in HCV genotype-1-6/HIV-1 coinfected adults with and without compensated cirrhosis for 8 and 12 weeks, respectively. Patients were either HCV treatment-naïve or experienced with sofosbuvir, ribavirin or interferon, and antiretroviral therapy (ART)-naïve or on a stable ART regimen for at least 8 weeks. The primary endpoint was the proportion of patients with sustained virologic response 12 weeks post-treatment (SVR12). Among the details:
- 153 patients were enrolled, including 16 (10%) with cirrhosis.
- SVR12 rate was 98% with no virologic failures in the 137 patients treated for 8 weeks.
- Most adverse events were mild.
- All patients treated with ART maintained HIV-1 suppression during treatment.
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: The EXPEDITION-2 study. [Published online ahead of print March 16, 2018]. Clin Infect Dis. doi:10.1093/cid/ciy220.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al